AB

Abbott India LtdNSE ABBOTINDIA

Последний отчетный период 31 мар., 2024

Обновлено 18 сент., 2024

Последняя цена

Капитализация млрд. $

2.012

Small

Биржа

XNSE - National Stock Exchange Of India

Анализ акций ABBOTINDIA.NS

AB

Нет оценки

Количественный анализ Eyestock не покрывает акции Abbott India Ltd.

Капитализация млрд. $

2.012

Дивидендная доходность

2.55 %

Оборот

21.249 млрд

Сайт компании

https://www.abbott.co.in/

Abbott India Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 3,700 full-time employees. The firm has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. The company provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. The company offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.

Смотреть Секцию: Рейтинг